

AMENDMENTS TO THE CLAIMS

1-25. (Cancelled)

26. (Currently amended) A method for detecting the presence of a cancer an aberrant cell in a subject or in a biological sample from said subject, said method comprising screening said subject or biological sample from said subject for the level of an expression product of a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 4, a polynucleotide that encodes SEQ ID NO: 6 and a polynucleotide sequence having 95% identity to either of the foregoing ~~the level of an expression product of a gene encoding a StarD10 in said biological sample~~, wherein an elevated level of said expression product in said sample compared to a normal level of said expression product when no cancer aberrant cells are present is indicative of the presence of said cancer aberrant cell.

27-32. (Cancelled)

33. (Currently amended) The method of Claim 26, wherein said expression product is a polypeptide, said method comprising contacting cells or cell extracts from said subject or said biological sample with an immunointeractive molecule specific for said polypeptide StarD10 or an antigenic portion thereof and screening for the level of immunointeractive molecule-polypeptide StarD10 complex formations, wherein an elevated presence of said complex relative to a normal cell is indicative of the presence of said cancer aberrant cell.

34. (Currently amended) The method of Claim 33, wherein the immunointeractive molecule is an antibody having specificity for said polypeptide StarD10 or an antigenic determinant or epitope thereon and wherein the screening comprises quantitatively or qualitatively determining the level of a polypeptide-StarD10-antibody complex.

35. (Withdrawn, currently amended) The method of Claim 26, wherein said expression product is an mRNA molecule, said method comprising:

obtaining mRNA from cells of said subject or from a biological sample from said subject and optionally generating cDNA from said mRNA;

contacting said mRNA or cDNA with a genetic probe capable of hybridizing to and/or amplifying all or part of a nucleotide sequence encoding selected from the group consisting of SEQ ID NO: 4, a polynucleotide that encodes SEQ ID NO: 6 and a

polynucleotide sequence having 95% identity to either of the foregoing StarD10 or its complementary nucleotide sequence; and then

detecting the level of said mRNA or cDNA; and

comparing the detected level of said mRNA or cDNA with a level of said mRNA or cDNA from normal controls, wherein the detection of elevated levels of said mRNA or cDNA compared to said normal controls is indicative of the presence of said cancer aberrant cell.

36. **(Currently amended)** The method of any one of Claims 26, 33 or ~~34~~ 35, wherein the sample is a biopsy comprising biological material selected from the group consisting of: cells, cell extract, tissue, tissue fluid, excretia, circulatory fluid, respiratory fluid, and other material.

37. **(Withdrawn)** The method of claim 35, wherein said genetic probe comprises a nucleotide sequence substantially as set forth in SEQ ID NO: 4 or a part or fragment thereof or a nucleotide sequence having at least about 80% identity with SEQ ID NO: 4 or a part or fragment thereof.

38. **(Withdrawn)** The method of claim 37 wherein said nucleotide sequence has at least 95% identity with SEQ ID NO: 4 or a part or fragment thereof.

39. **(Withdrawn)** The method of claim 35, wherein the contacting step comprises quantitative amplification of the mRNA or cDNA.

40. **(Withdrawn)** The method of claim 35, wherein the detecting step comprises Northern analysis.

41. **(Withdrawn)** he method of claim 35, wherein the contacting step is carried out under low stringency conditions (6X SSC buffer, 0.1% w/v SDS at a temperature in the range from 25°C to 42°C) or more stringent conditions.

42. **(Withdrawn)** The method of claim 41, wherein the contacting step is carried out under moderate stringency conditions (2X SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to about 65°C) or more stringent conditions.

43. **(Withdrawn)** The method of claim 42, wherein the contacting step is carried out under high stringency conditions (0.1X SSC buffer, 0.1% w/v SDS at a temperature greater than 65°C) or more stringent conditions.

44. **(Withdrawn)** The method of Claim 35, wherein the genetic probe comprises at least 12 consecutive nucleotides from SEQ ID NO:4.

45. **(Withdrawn)** The method of Claim 44, wherein the genetic probe comprises 15-18 consecutive nucleotides from SEQ ID NO:4.

46. **(Withdrawn)** The method of Claim 44, wherein the genetic probe comprises at least 25 consecutive nucleotides from SEQ ID NO:4.

47. **(Canceled)** ~~The method of any one of Claims 26, 33 or 35, wherein the aberrant cell is a cancer cell or a cell.~~

48. **(Canceled)** ~~The method of any one of Claims 26, 33 or 35, wherein the aberrant cell is a cell of a cancer-like growth.~~

49. **(New)** A method for detecting the presence of a cancer cell in a subject or in a biological sample from said subject, said method comprising:

contacting a tissue from said subject or said biological sample with an antibody specific for a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6 and a sequence having 95% identity to either of the foregoing, for a time and under conditions sufficient for a complex between said antibody and said polypeptide to form, and

determining the level of said complex,

wherein an elevated level of said complex in said sample compared to a normal level of said complex when no cancer cells are present is indicative of the presence of said cancer cell.

50. **(New)** The method of Claim 26 or Claim 49, wherein said cancer cell is a breast cancer cell.